Immune’s subsidiary, CYTOVIA, to implement development and commercialization plan for Ceplene NEW YORK, June 20, 2017 /PRNewswire/ — Immune Pharmaceuticals (NASDAQ:IMNP) (“Immune”), a clinical stage biopharmaceutical company, announced today that patient enrollment in a Phase I/II clinical trial evaluating the safety and efficacy of Ceplene (histamine dihydrochloride) in patients with Chronic Myelomonocytic Leukemia (CMML) is expected…